insights_auto
Mengapa 8NE naik 3,28%?
Pelajari Lebih Lanjutchevron_right
8NE:FRA
Lisata Therapeutics, Inc.
€0,94
arrow_upward
+3,28%(+0,030) 1 HR
9 Okt, 08.05.36 GMT+2 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk 8NE...
Pembukaan
€0,94
Tinggi
€0,94
Rendah
€0,94
Kapitalisasi pasar
11,24 jt
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
€4,34
Harga rendah dalam 52 minggu terakhir
€0,74
Jumlah karyawan
21
Pembukaan
€0,94
Tinggi
€0,94
Rendah
€0,94
Kapitalisasi pasar
11,24 jt
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
€4,34
Harga rendah dalam 52 minggu terakhir
€0,74
Jumlah karyawan
21
Artikel berita
Dari sumber web dan partner berita
Investing.com
·
1 hari yang lalu
Lisata Therapeutics receives patent for certepetide cancer treatment
Stock Titan
·
1 hari yang lalu
A new cancer-treatment patent adds market exclusivity into 2043, Lisata says.
Investing.com UK
·
1 hari yang lalu
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com
Profil
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Tentang Lisata Therapeutics, Inc.
CEO-
Karyawan21
Didirikan1980
Kantor PusatBasking Ridge, New Jersey, Amerika Serikat
Sektor-
Situslisata.com